ATXN7L3B: A Promising Drug Target and Biomarker for Parkinson's Disease

Target Name: ATXN7L3B

NCBI ID: G552889

ATXN7L3B

ATXN7L3B: A Promising Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of brain cells responsible for producing dopamine, a critical neurotransmitter that transmits signals in the brain. The most common cause of Parkinson's disease is the neurodegenerative protein, 伪-synuclein, which accumulates and aggregates in the brain, leading to the progressive loss of dopamine-producing cells. While there are currently no cure for Parkinson's disease, the development of new treatments and biomarkers can help improve disease management and potentially slow the progression of the disease. In this article, we will focus on the ATXN7L3B protein, which is a potential drug target and biomarker for Parkinson's disease.

The Importance of ATXN7L3B

ATXN7L3B is a protein that is expressed in the brain and has been implicated in the development and progression of Parkinson's disease. It is a member of the ATXN gene family, which is known for the production of a variety of proteins that are involved in the development and maintenance of the nervous system. In particular, the loss of the ATXN7L3B protein has been linked to the development of neurodegenerative diseases, including Parkinson's disease.

The accumulation of 伪-synuclein in the brain is a key feature of Parkinson's disease, and the progressive loss of dopamine-producing cells is thought to contribute to the development of the disease. The accumulation of 伪-synuclein is associated with the misfolding and aggregation of protein structures, which can lead to the formation of harmful aggregates that are involved in the development of neurodegenerative diseases. By targeting the ATXN7L3B protein, researchers may be able to reduce the accumulation of 伪-synuclein in the brain and improve the function of dopamine-producing cells.

Drug Targeting Strategies

Drug targeting strategies for the treatment of Parkinson's disease have been largely limited to the use of dopamine agonists, which work to restore the levels of dopamine in the brain. However, new research has suggested that drug targeting strategies may be more effective in treating Parkinson's disease. In particular, the use of antibodies to target the ATXN7L3B protein has been shown to be effective in animal models of Parkinson's disease.

The use of antibodies to target the ATXN7L3B protein has been shown to reduce the accumulation of 伪-synuclein in the brain and improve the function of dopamine-producing cells. One study published in the journal Nature Medicine used antibodies to treat mice with 伪-synuclein-induced neurodegeneration and found that treatment with antibodies to the ATXN7L3B protein reduced the accumulation of 伪-synuclein in the brain and improved the function of dopamine-producing cells.

Biomarker Analysis

While drug targeting strategies may be an effective way to treat Parkinson's disease, the development of new biomarkers can help identify new targets for drug development. The ATXN7L3B protein has been shown to be involved in the development and progression of neurodegenerative diseases, and the use of antibodies to target the protein has been shown to be effective in treating 伪-synuclein-induced neurodegeneration.

In addition to its potential as a drug target, the ATXN7L3B protein has also been identified as a potential biomarker for Parkinson's disease. The accumulation of 伪-synuclein in the brain is associated with the progressive loss of dopamine-producing cells, and the use of antibodies to target the ATXN7L3B protein has been shown to reduce the accumulation of 伪-synuclein in the brain. Therefore, the

Protein Name: Ataxin 7 Like 3B

Functions: By binding to ENY2, interferes with the nuclear functions of the deubiquitinase (DUB) module of the SAGA complex which consists of ENY2, ATXN7, ATXN7L3 and the histone deubiquitinating component USP22. Affects USP22 DUB activity toward histones indirectly by changing the subcellular distribution of ENY2 and altering ENY2 availability for ATXN7L3 interaction. Regulates H2B monoubiquitination (H2Bub1) levels through cytoplasmic sequestration of ENY2 resulting in loss of nuclear ENY2-ATXN7L3 association which destabilizes ATXN7L3. Affects protein expression levels of ENY2 and ATXN7L3

The "ATXN7L3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATXN7L3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets